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See Article, pages 12–18The primary goal of antiviral treatment of chronic hepatitis B is to
achieve sustained suppression of hepatitis B virus (HBV) replica-
tion to an undetectable level, thus preventing or reducing the
complications of cirrhosis, hepatic decompensation, hepatocellu-
lar carcinoma, and death [1]. It logically follows that a concomi-
tant and equally important goal of therapy is to achieve a high
rate of patient adherence to antiviral treatment when using a
nucleos(t)ide (NUC) analogue, which requires long-term and
potentially lifelong administration. It is reasonable to assume
that non-adherence can result in poor virologic suppression,
breakthrough resistance, and progression of disease, although
the contribution of non-adherence to these outcomes is uncertain
[2]. However, in order to study the association between adher-
ence and the outcomes of antiviral therapy of chronic hepatitis
B, it is important to determine ﬁrst the medication adherence
rate that occurs in practice. In this issue, Chotiyaputta et al. [3]
have published the ﬁrst, large-scale evaluation of patient adher-
ence with HBV oral antiviral therapy, as well as some of the fac-
tors associated with adherence, from a retrospective population-
based study of 11,100 patients with chronic hepatitis B.
Adherence (synonymous with compliance, or concordance) with
medication usage is deﬁned as the proportion of prescribed doses
of medication actually taken by a patient over a speciﬁed period
of time [4], and has been extensively studied in various chronic
medical conditions, including hypertension, hyperlipidemia, and
human immunodeﬁciency virus (HIV) infection/acquired
immune deﬁciency syndrome (AIDS). Although the preferred ter-
minology remains a matter of debate, theWorld Health Organiza-
tion (WHO) and a number of other agencies have selected
adherence as the preferred term [5]. Compliance, which was
commonly used in the past, implies a passive role and simply fol-
lowing the demands of a prescriber, and non-compliance has
been regarded as associated with deviant or irrational behavior.
Adherence, on the other hand, implies an active role in collabora-
tion with a prescriber, and non-adherence encompasses the
diverse reasons for patients not following a treatment recom-
mendation, including the characteristics of the disease, social
and economic factors, the health care team and system, and cost
of medications as well as a number of patient-related factors.Journal of Hepatology 20
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to be high, at approximately 90% or more, but patient adherence
rates with medication used for chronic conditions in clinical prac-
tice are highly variable. The WHO has identiﬁed poor adherence
to treatment as a worldwide problem, with adherence to therapy
of chronic illnesses in developed countries estimated to average
only 50%, with lower rates in developing countries [5]. With
respect to statin therapy for hyperlipidemia, adherence rates for
secondary prevention range between 81% and 94% [6,7], with a
dramatic drop-off after 6 months [8–10], whereas antihyperten-
sive therapy adherence rates are even lower between 50% and
75% [11–13]. Although the medication regimens for hyperlipid-
emia and hypertension are relatively uncomplicated, consisting
of a single medication dose once daily (at least during the initial
stages of disease) as compared to the highly active antiretroviral
therapy (HAART) regimen for HIV treatment, these adherence
rates are still unfortunately low. Furthermore, in general, adher-
ence rates can only be expected to decrease as additional doses or
extra medications are required, with an estimated 10% stepwise
decrease in the mean adherence rate for each additional daily
dose of medication, such as required with HAART in patients with
HIV infection [14]. Finally, non-adherence has signiﬁcant nega-
tive health impacts, such as a stepwise reduction in viral suppres-
sion and progression to AIDS and death in HIV infection [15,16],
and myocardial infarction and stroke in poorly controlled hyper-
tension [4,5].
Antiviral therapy for chronic hepatitis B would appear to pos-
sess a proﬁle favoring high adherence rates given the once daily
dosing of a single NUC analogue, which is usually well tolerated
with minimal side effects. However, patients with chronic hepa-
titis B may face barriers to adherence similar to those found in
other chronic medical conditions, such as lack of symptoms dur-
ing the early stage of disease that may be associated with uncer-
tainty regarding the beneﬁcial impact of the prescribed
medication on overall health and, therefore, an equivocal need
for treatment. Other common reasons affecting patient adher-
ence, such as forgetfulness, overriding priorities, emotional or
cultural factors, may be expected to occur in patients prescribed
NUC therapy [17]. Provider factors affecting medication adher-
ence, such as properly communicating the intention and beneﬁts
of treatment, are also important.
In their retrospective population-based study, Chotiyaputta
et al. [3] speciﬁcally evaluated patient-oriented adherence with11 vol. 54 j 6–8
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antiviral therapy in terms of both actual medication possession
by a patient during its prescribed period (the adherence rate)
and the rate of continuing to reﬁll prescriptions during its pre-
scribed period (the persistence rate) by studying a large pharmacy
claims database, which represented 25% of the American market
for hepatitis B treatment. The study population included an over-
all total population of 11,100 patients with chronic hepatitis B
(comprised of three smaller, but similarly sized, annual cohorts),
who were receiving one of several NUCs (lamivudine, adefovir,
entecavir, tenofovir) between 2007 and 2009. A vast majority
(10,582 or 95.3%) of these patients had existing prescriptions
prior to their enrollment into an annual cohort, while only a very
small minority (518 or 4.7%) of patients was started on a new
prescription upon cohort enrollment. Demographic (age and gen-
der) and medical insurance status data were only available for
the 2008 and 2009 cohorts, which consisted of 7405 patients
(66.7%).
The overall adherence rate between 2007 and 2009 was
remarkably high, with a mean of 87.8% and median of 93.2% hav-
ing medications in their possession. Approximately half of all
patients (55.3%) had an adherence rate of more than 90%, while
15.9% of all patients had adherence rates 670% and only 5.7% of
all patients had adherence rates 650%. Patients who received
new prescriptions also had similar adherence rates of 84.6%, with
half of new patients having an adherence rate of more than 90%
and only 9.2% of new patients with adherence rates 650%. Given
the very low number of new patients to compare to, the differ-
ence in these rates was not likely to be clinically signiﬁcant. Nev-
ertheless, it was still promising to see that adherence rates with
antiviral therapy compared favorably to, or better than, those
reported with treatment of hypertension and hyperlipidemia.
From the multivariate analysis of the 2008 and 2009 cohorts,
independent predictors of good adherence included patients
older than 45 years and those who were prescribed NUCs other
than lamivudine. Patients who were already receiving antiviral
therapy were also more likely to be adherent than those starting
therapy; however, the duration of their existing therapy, which
may be an important predictor of adherence, was unknown.
Similar to the rates of adherence, the overall persistence rate,
or rate of reﬁlling prescriptions, for patients between 2007 and
2009 was almost as high at 81%. As seen with other chronic med-
ical conditions, there was a rapid drop-off in persistence within
the ﬁrst 6 months of cohort enrollment; the persistence rate
declined by 9.1% and 22.4% by 6 months in existing and new
patients, respectively. The decline in persistence among most
NUCs had similar slopes, but interestingly, patients with new pre-
scriptions for either lamivudine or tenofovir experienced the
largest drop-off in persistence, declining to 65% after 6 months.
A follow-up study from the same unit reported in preliminary
fashion a discrepancy between virologic breakthrough and con-
ﬁrmed genotypic resistance in patients with chronic hepatitis B
undergoing NUC therapy, suggesting that medication non-adher-
ence was an important cause of virologic breakthrough [18]. This
study was a retrospective review of 112 patients with chronic
hepatitis B treated with an NUC analogue for more than one year
from January 2001 to October 2009. The index treatment
included lamivudine (n = 28), adefovir (n = 18), entecavir
(n = 38), tenofovir (n = 13), telbivudine (n = 1), Truvada (combi-
nation tenofovir and emtricitabine) (n = 5), or other combination
of NUCs (n = 9). The cumulative incidence of virologic break-
through at 3 and 5 years was 34% and 58%, and the incidence ofJournal of Hepatology 2conﬁrmed genotypic resistance was 18% and 41%, respectively,
at the same time points. Of 24 NUC-naïve patients receiving lam-
ivudine, 13 had virologic breakthrough and seven had genotypic
resistance; by contrast, of 26 NUC-naïve patients receiving ente-
cavir, six had virologic breakthrough and none had genotypic
resistance. Overall, only 49% of patients with virologic break-
through were conﬁrmed to have genotypic resistance, suggesting
that medication non-adherence is an important cause of break-
through. The obvious recommendation from this study is that
mutation testing should be performed prior to switching treat-
ment with the occurrence of virologic breakthrough, especially
for patients receiving an NUC with a high genetic barrier to
resistance.
In summary, Chotiyaputta et al. [3] have conducted the ﬁrst
large-scale study of patient adherence with antiviral therapy for
chronic hepatitis B in a real-world practice setting outside of clin-
ical trials, and they have shown that the overall adherence and
persistence rates are both high at 87.8% and 81%, respectively.
While it may be argued that possession of medication does not
represent its actual utilization, the converse (i.e., failing to pos-
sess or continue to reﬁll medications) does represent a failure
of adherence. As expected, antiviral therapy was still found to
be subject to the same rapid decline in persistence after several
months of treatment as reported for medication treatment of
other chronic conditions [8–13]. It remains unclear whether this
decline is a function of generalized medication fatigue, and fur-
ther study will be needed to determine what additional factors,
both patient- and provider or health system-oriented, affect this
rapid decline. Adherence with use of NUCs requires study in var-
ious patient and practice situations, e.g., in tertiary and primary
care practices, among patients with various educational levels
and socioeconomic status, in health plans with different out-of-
pocket costs to patients, and in speciﬁc patient ethnic popula-
tions. A number of important questions related to adherence can-
not be correlated or explained from studies based upon pharmacy
records, but the study of Chotiyaputta and colleagues is an
important ﬁrst step that should be a stimulus for future prospec-
tive studies to address the complex patient and provider issues
associated with rates of adherence and the sequelae of non-
adherence. The results of such future studies should lead to inter-
ventions aimed at improving adherence in speciﬁc practice set-
tings and enhance the effectiveness of the treatment of chronic
hepatitis B with NUC analogues.Conﬂict of interest
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